Coversyl (perindopril) is a long-acting ACE inhibitor with a high affinity for tissue ACE. Due to its unique mechanism of action, proven efficacy, hemodynamic tolerance and cardiovascular properties, Coversyl is a first-line choice agent in the treatment of hypertension at the dosage of 4 mg to 8 mg if greater BP decrease is needed, or if patients is already at higher risk.

Coversyl is also indicated at the initial dosage of 4 mg for 2 weeks, then 8 mg in stable coronary artery disease to decrease cardiac events, and in heart failure at the initial dosage of 2 mg and 4 mg maintenance dosage. Coversyl was chosen in landmark morbidity mortality trials: ASCOT, EUROPA, PREAMI, and PROGRESS.